Senate Finance Committee Hearing on Abortion Drug Safety

The Restoration of America Foundation (ROAF) is urging the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable during a hearing scheduled for Thursday at 10 AM. The foundation is questioning the recent removal of safety protocols related to the abortion drug Mifepristone.

In a letter addressed to the committee, ROAF expresses concerns that lifting these restrictions puts women at greater risk and shifts the financial burden onto taxpayers.

Specifically, ROAF argues that the Biden administration’s decision to relax risk assessment and mitigation strategies, which had been in place for over two decades, endangers women’s health. The organization highlights the ability to prescribe abortion medications through telehealth and send them by mail as particularly troubling.

Previously, the FDA mandated that Mifepristone be dispensed in a way that ensured proper medical screening to identify potential complications, such as ectopic pregnancies. However, under the current administration, new policies have allowed prescriptions to be made via telehealth with mail delivery.

In a call for action, ROAF stated, “The removal of Mifepristone’s essential risk assessment requirements has stripped away important protections that have safeguarded women’s health for over 20 years.” They are asking for clarity regarding the reasons behind these changes and when, if at all, these safety measures might be reinstated.

Furthermore, some GOP lawyers are echoing ROAF’s concerns, advocating for the revival of protective measures for abortion medications. There’s significant worry that distributing these potent drugs online without medical checks could pose serious risks to women. One lawyer pointed out that women should be informed about potential complications and should have swift access to emergency care if needed.

An alarming statistic surfaced from a survey indicating that nearly 11% of chemical abortions lead to severe health complications, which is reportedly more than twenty times higher than what the FDA had previously suggested.

The upcoming hearing, with Kennedy expected to address these topics, promises to spotlight ongoing discussions around abortion and medical safety. As of now, HHS has not provided a comment on these pressing concerns.